SCHEMBL23475665

SCHEMBL23475665

C/N=C/N(C)S(=O)(=O)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ BCAT1 P54687 1/20 0.46
▸ APOBEC3G Q9HC16 1/20 0.45
▸ HSD11B1 P28845 1/20 0.44
▸ ALDH1A1 P00352 4/20 0.42
▸ HTR2A P28223 1/20 0.42
▸ HTR2C P28335 1/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ CA12 O43570 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ NR1I2 O75469 1/20 0.39
▸ CCR5 P51681 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27637183 0.78 APOBEC3G (0.50) BCAT1APOBEC3GHSD11B1ALDH1A1HTR2A
SCHEMBL19021881 0.76 APOBEC3G (0.48) BCAT1APOBEC3GHSD11B1ALDH1A1HTR2A
SCHEMBL14855030 0.73 HSD11B1 (0.53) APOBEC3GHSD11B1ALDH1A1KMT2AKDM4E
SCHEMBL182738 0.72 LMNA (0.67) APOBEC3GHSD11B1ALDH1A1KMT2AKDM4E
SCHEMBL26413509 0.72 APOBEC3G (0.58) APOBEC3GHSD11B1ALDH1A1HTR2AHTR2C
SCHEMBL11211293 0.72 APOBEC3G (0.58) APOBEC3GHSD11B1ALDH1A1HTR2AHTR2C
SCHEMBL28365619 0.72 APOBEC3G (0.44) BCAT1APOBEC3GHSD11B1ALDH1A1HTR2A
SCHEMBL10954851 0.71 APOBEC3G (0.52) BCAT1APOBEC3GHSD11B1ALDH1A1HTR2A
SCHEMBL4110091 0.71 LMNA (0.70) BCAT1ALDH1A1HTR2AHTR2CKMT2A
SCHEMBL4972178 0.71 LMNA (0.70) BCAT1ALDH1A1HTR2AHTR2CKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171522-A1 DERIVATIVES OF AN FGFR INHIBITOR INCYTE CORPORATION 2021-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171522-A1 DERIVATIVES OF AN FGFR INHIBITOR FGFR1, FGFR2, FGFR4 BCAT1 831/4885APOBEC3G 4576/4885HSD11B1 266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback